Feedback / Questions
Cinvanti (aprepitant IV) - Heron Therapeutics
Cinvanti: Patent exclusivity in US until March 2036
(Heron Therapeutics)
-
Oct 10, 2017 -
Corporate Presentation
Patent
•
Oncology
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjgwMzQ5fENoaWxkSUQ9Mzg5NzI5fFR5cGU9MQ==&t=1
Oct 10, 2017
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious